The role of nutritional support of human immunodeficiency virus (HIV) infected patients on antiretroviral treatment

The role of nutritional support of human immunodeficiency virus (HIV) infected patients on antiretroviral treatment: a randomised trial in Jimma, Ethiopia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN32453477

Enrollment

400

Registered

2010-10-04

Start date

2010-07-19

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human immunodeficiency virus (HIV) infection Infections and Infestations Human immunodeficiency virus (HIV)

Interventions

200 g per day of a RUSF containing whey or soy protein for three months from the start of ART, or no supplement for the first three months, but the same supplement from three to six months after the s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. HIV-infected adults (aged greater than or equal to 18 years, either sex) commencing ART 2. Living within approximately 50 km from Jimma 3. Consenting to participate

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating 2. Terminally ill from HIV or other serious condition 3. Patients who may not be able to consume RUSF due to extensive oral lesion 4. Patients with nutritional oedema

Design outcomes

Primary

Measure	Time frame
Change over the first three months in: 1. Lean body mass as assessed using deuterium dilution test 2. Grip strength as assessed using a dynamometer 3. Physical activity assessed using a combined accelerometer and heart rate monitor	—

Secondary

Measure	Time frame
Measured after three months: 1. ART drug levels 2. HIV load and CD4 counts 3. Adherence to ART and quality of life 4. IGF-1	—

Countries

Ethiopia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026